TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31133096

Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle intervention (reducing sodium intake, weight control, exercise, quitting smoking, limiting alcohol consumption)
Number of subjects: 1183

Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle intervention
Number of subjects: 1183

Group type: COMPARATOR
Intervention: Control group (no active intervention)
Number of subjects: 1183
Study: 28663620

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 26088909

Group type: EXPERIMENTAL
Intervention: Intensive control (target BG range of 4.5‐6.0 mmol/L)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Conventional control (target BG <10 mmol/L)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Intensive control
Number of subjects: 391

Group type: COMPARATOR
Intervention: Conventional control
Number of subjects: 391
Study: 23508563

Group type: EXPERIMENTAL
Intervention: Forearm tourniquet
Number of subjects: 56

Group type: COMPARATOR
Intervention: Upper arm tourniquet
Number of subjects: 56
Study: 21525248

Group type: EXPERIMENTAL
Intervention: 2.5 g L-leucine with each main meal (7.5 g/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo with each main meal
Number of subjects: 60
Study: 19220847

Group type: EXPERIMENTAL
Intervention: Nanocrystalline hydroxyapatite silica gel (Group 1, 3 months healing)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nanocrystalline hydroxyapatite silica gel (Group 2, 6 months healing)
Number of subjects: 16
Study: 16421464

Group type: EXPERIMENTAL
Intervention: Adherent patients
Number of subjects: 1031

Group type: COMPARATOR
Intervention: Non-adherent patients
Number of subjects: 1031
Study: 12682468

Group type: EXPERIMENTAL
Intervention: Ibutilide 0.008 mg/kg body weight over 10 mins; if needed, amiodarone 5 mg/kg over 30 mins and 15 mg/kg over 24 hrs
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amiodarone 5 mg/kg over 30 mins and 15 mg/kg over 24 hrs
Number of subjects: 40
Study: 11104872

Group type: EXPERIMENTAL
Intervention: Iodixanol (320 mg I/ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ioxaglate (320 mg I/ml)
Number of subjects: 0
Study: 8613058

Group type: EXPERIMENTAL
Intervention: UDCA (13-15 mg.kg-1.day-1)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 1446728

Group type: EXPERIMENTAL
Intervention: GM-CSF (3 micrograms/kg/day s.c.) alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: GM-CSF plus AraC (20 mg/m2/d s.c.)
Number of subjects: 21
Study: 3001664

Group type: EXPERIMENTAL
Intervention: ACTH 4-9 analog (5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ACTH 4-9 analog (10 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ACTH 4-9 analog (20 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: d-amphetamine (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 10
Study: 30007274

Group type: EXPERIMENTAL
Intervention: Fat grafting (Group 1)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Fat grafting (Group 2)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fat grafting (both groups)
Number of subjects: 23
Study: 30063588

Group type: EXPERIMENTAL
Intervention: Computer-assisted total knee replacement
Number of subjects: 190
Study: 27389084

Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24281134

Group type: EXPERIMENTAL
Intervention: Rolofylline
Number of subjects: 2033

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2033

Group type: EXPERIMENTAL
Intervention: All variables (including 37 clinical characteristics)
Number of subjects: 2033

Group type: EXPERIMENTAL
Intervention: Simplified model (using 8 items)
Number of subjects: 2033
Study: 22554123

Group type: EXPERIMENTAL
Intervention: Orange roughy oil
Number of subjects: 46

Group type: COMPARATOR
Intervention: Petrolatum (Vaseline)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 46
Study: 20919777

Group type: EXPERIMENTAL
Intervention: Cavalier humor beliefs (CHB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Jokes targeting low-status outgroup (Mexicans)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pretest-posttest design
Number of subjects: 0
Study: 18393056

Group type: EXPERIMENTAL
Intervention: Gambling
Number of subjects: 452

Group type: COMPARATOR
Intervention: Substance use/conduct disorder
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Gambling preferences/frequency
Number of subjects: 452
Study: 16080909

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra) 100 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 11923794

Group type: EXPERIMENTAL
Intervention: Bivalirudin 1.0 mg/kg bolus followed by a 4-hour infusion at 2.5 mg/kg/h
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bivalirudin 0.75 mg/kg bolus followed by a 4-hour infusion at 1.75 mg/kg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Heparin 60 U/kg bolus
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All treatment groups (including bivalirudin and heparin) with eptifibatide
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bivalirudin and Heparin
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 42
Study: 10793302

Group type: EXPERIMENTAL
Intervention: Self-managed meal-replacement weight-control program (MR)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 158
Study: 8780425

Group type: EXPERIMENTAL
Intervention: Psychiatric Research Interview for Substance and Mental Disorders (PRISM)
Number of subjects: 172
Study: 1321858

Group type: COMPARATOR
Intervention: RRV (VP7 serotype 3)
Number of subjects: 223

Group type: COMPARATOR
Intervention: DxRRV (VP7 serotype 1)
Number of subjects: 223
Study: 6430326

Group type: EXPERIMENTAL
Intervention: Cyclandelate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30719861

Group type: EXPERIMENTAL
Intervention: Occlutech Figulla Flex II occluder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amplatzer Septal Occluder
Number of subjects: 0
Study: 29178495

Group type: EXPERIMENTAL
Intervention: 1450-nm diode laser (DL)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fractional microneedling radiofrequency (FMR)
Number of subjects: 25
Study: 26762374

Group type: EXPERIMENTAL
Intervention: Plant stanol enriched soy-based yogurts (4.0 g plant stanols/d)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control soy-based yogurt without added plant stanol esters
Number of subjects: 58
Study: 24447074

Group type: EXPERIMENTAL
Intervention: Predictive low glucose management (PLGM) system
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low glucose suspend (LGS)
Number of subjects: 22
Study: 23180952

Group type: EXPERIMENTAL
Intervention: Probiotics (3 × 10(7)Lactobacillus acidophilus per day) for two weeks prior to triple therapy
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Probiotics (3 × 10(7)Lactobacillus acidophilus per day) for two weeks after triple therapy
Number of subjects: 234

Group type: COMPARATOR
Intervention: Standard triple therapy (omeprazole 20 mg bid, clarithromycin 500 mg bid, and amoxicillin 1000 mg bid)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Probiotics (3 × 10(7)Lactobacillus acidophilus per day) for two weeks prior to or after triple therapy
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Symptom relief
Number of subjects: 234
Study: 19925528

Group type: EXPERIMENTAL
Intervention: Cilnidipine 10-20 mg once daily for 4 weeks
Number of subjects: 196

Group type: COMPARATOR
Intervention: Losartan 50-100 mg once daily for 4 weeks
Number of subjects: 196

Group type: COMPARATOR
Intervention: Cilnidipine vs Losartan
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Cilnidipine and Losartan
Number of subjects: 196
Study: 19034343

Group type: EXPERIMENTAL
Intervention: External shielding of the testis during pelvic radiotherapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: No external shielding of the testis during pelvic radiotherapy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Phantom measurements
Number of subjects: 19
Study: 28025969

Group type: EXPERIMENTAL
Intervention: Test preparation (valsartan tablet)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference preparation (valsartan tablet)
Number of subjects: 18
Study: 11140029

Group type: EXPERIMENTAL
Intervention: Competency-based primary care drug therapy (PCDT) training programme
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 66
Study: 9270083

Group type: EXPERIMENTAL
Intervention: Alpha-blocker (terazosin)
Number of subjects: 45
Study: 8296255

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms twice daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 3325318

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline capsules
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard slow-release theophylline tablets
Number of subjects: 30
Study: 2584664

Group type: EXPERIMENTAL
Intervention: Simethicone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31087650

Group type: EXPERIMENTAL
Intervention: Early stage diagnosis (stages I and II)
Number of subjects: 2311

Group type: EXPERIMENTAL
Intervention: Advanced stage diagnosis (stages III and IV)
Number of subjects: 2311

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 2311

Group type: EXPERIMENTAL
Intervention: Patients diagnosed in late stages
Number of subjects: 2311

Group type: EXPERIMENTAL
Intervention: Registry-specific survival
Number of subjects: 2311

Group type: EXPERIMENTAL
Intervention: Age at diagnosis
Number of subjects: 2311
Study: 31302440

Group type: EXPERIMENTAL
Intervention: tDCS (transcranial Direct Current Stimulation)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: TMS (Transcranial Magnetic Stimulation)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: ECT (Electroconvulsive Therapy)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Overall NIBS studies
Number of subjects: 22
Study: 27714649

Group type: EXPERIMENTAL
Intervention: Telephone-delivered stepped collaborative care (CC)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Watchful waiting (WW)
Number of subjects: 329
Study: 26003546

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerobic exercise and Mediterranean diet (combined)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 23232039

Group type: EXPERIMENTAL
Intervention: Tobramycin nebuliser solution 300 mg/4 mL (TNS4) via PARI eFlow(®) rapid nebuliser
Number of subjects: 27

Group type: COMPARATOR
Intervention: Tobramycin nebuliser solution 300 mg/4 mL (TNS4) via PARI LC Plus(®) nebuliser
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tobramycin nebuliser solution 300 mg/4 mL (TNS4)
Number of subjects: 27
Study: 21383098

Group type: EXPERIMENTAL
Intervention: Coadministration of 150 mg maraviroc b.i.d. with darunavir-ritonavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coadministration of 300 mg maraviroc b.i.d. with etravirine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coadministration of 150 mg maraviroc b.i.d. with etravirine-darunavir-ritonavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maraviroc with darunavir-ritonavir, etravirine, or both
Number of subjects: 0
Study: 19246721

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16298542

Group type: EXPERIMENTAL
Intervention: Fuzzy Logic Controller (FLC)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Self-Organizing Fuzzy Logic Controller (SOFLC)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional Rule-Based Controller (RBC)
Number of subjects: 17
Study: 15273033

Group type: EXPERIMENTAL
Intervention: Home telehealth nursing service
Number of subjects: 12
Study: 11217680

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba special extract EGb 761
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo or reference drugs
Number of subjects: 19
Study: 9051392

Group type: EXPERIMENTAL
Intervention: Training plus BCAA supplement
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Training plus placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sedentary plus BCAA supplement
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sedentary plus placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Physical training (overall)
Number of subjects: 24

Group type: COMPARATOR
Intervention: BCAA supplementation
Number of subjects: 24
Study: 8364776

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) 300 mg 1 hour before each meal and at bedtime (n = 16)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid (n = 12)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg b.i.d.) plus metronidazole (250 mg t.i.d; n = 14)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 42
Study: 3753801

Group type: EXPERIMENTAL
Intervention: Ivermectin (200 micrograms per kilogram of body weight, single oral dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diethylcarbamazine or placebo
Number of subjects: 0
Study: 29195025

Group type: EXPERIMENTAL
Intervention: CLM + BUD (clarithromycin 0.25 g/d and budesonide 256 μg/d)
Number of subjects: 74

Group type: COMPARATOR
Intervention: BUD (budesonide 256 μg/d)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CLM + BUD
Number of subjects: 74

Group type: COMPARATOR
Intervention: BUD
Number of subjects: 74
Study: 27601539

Group type: EXPERIMENTAL
Intervention: Carfilzomib, Lenalidomide, and Dexamethasone (KRd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lenalidomide and Dexamethasone (Rd)
Number of subjects: 0
Study: 25175529

Group type: EXPERIMENTAL
Intervention: Social exchange with roommates across 5 weeks
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Perceived similarity measured in the second week
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Social exchange
Number of subjects: 214
Study: 20850895

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg weekly
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Etanercept (all dosages)
Number of subjects: 506
Study: 20385988

Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone)
Number of subjects: 1062

Group type: COMPARATOR
Intervention: CHOP (without rituximab)
Number of subjects: 1062
Study: 18241260

Group type: EXPERIMENTAL
Intervention: DHA 5.4 g daily (n = 21)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Isoenergetic control of saturated fatty acids (n = 23)
Number of subjects: 53
Study: 15931018

Group type: EXPERIMENTAL
Intervention: Relaxation Response (RR) intervention for 15 weeks, practicing techniques at home twice a day
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Cardiac education (EDU) program for 15 weeks
Number of subjects: 95

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 95
Study: 12881583

Group type: EXPERIMENTAL
Intervention: SPIO-enhanced MR imaging
Number of subjects: 134

Group type: COMPARATOR
Intervention: gadolinium-enhanced MR imaging
Number of subjects: 134
Study: 11025833

Group type: EXPERIMENTAL
Intervention: Linear peak clipper (PC) hearing aid circuit
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Compression limiter (CL) hearing aid circuit
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Wide dynamic range compressor (WDRC) hearing aid circuit
Number of subjects: 360

Group type: COMPARATOR
Intervention: Aided conditions (all circuits)
Number of subjects: 360
Study: 9069478

Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy (1H‐MRS) in patients with progressive supranuclear palsy
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy (1H‐MRS) in patients with idiopathic Parkinson's disease
Number of subjects: 13

Group type: COMPARATOR
Intervention: Healthy age matched controls
Number of subjects: 13
Study: 8347120

Group type: EXPERIMENTAL
Intervention: Arousal Training (bibliotherapy)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Urine device with specific instructions
Number of subjects: 127

Group type: COMPARATOR
Intervention: Urine alarm only
Number of subjects: 127
Study: 3558936

Group type: EXPERIMENTAL
Intervention: Heparin-bonded pulmonary-artery catheters
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-heparin-bonded pulmonary-artery catheters
Number of subjects: 20
Study: 31708063

Group type: EXPERIMENTAL
Intervention: Star rating-targeted medications (oral antidiabetic medications, RAS antagonists, statins)
Number of subjects: 1218104

Group type: COMPARATOR
Intervention: Nontargeted antihypertensive and antihyperlipidemic medications
Number of subjects: 1218104
Study: 29030894

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800 mg once-daily for 12 weeks
Number of subjects: 1703

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1200 mg once-daily for 12 weeks
Number of subjects: 1703

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1703
Study: 25559252

Group type: EXPERIMENTAL
Intervention: Discontinued-incentive condition receiving weekly incentives during fall semester 2011, and no incentives during spring semester 2012
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Continued-incentive condition receiving weekly incentives during fall semester, and incentives on a variable-interval schedule during spring semester
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control condition receiving no incentives for meeting fitness‐center attendance goals
Number of subjects: 117
Study: 23336578

Group type: EXPERIMENTAL
Intervention: Lower socioeconomic status (SES)
Number of subjects: 15934

Group type: EXPERIMENTAL
Intervention: Smoking, alcohol use, not working outside the home
Number of subjects: 15934

Group type: EXPERIMENTAL
Intervention: High triglycerides
Number of subjects: 15934

Group type: EXPERIMENTAL
Intervention: High HbA1c
Number of subjects: 15934

Group type: EXPERIMENTAL
Intervention: Raised fasting glucose
Number of subjects: 15934

Group type: EXPERIMENTAL
Intervention: High BMI
Number of subjects: 15934

Group type: EXPERIMENTAL
Intervention: High waist circumference
Number of subjects: 15934
Study: 21454845

Group type: EXPERIMENTAL
Intervention: SMS text message (n = 158)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Voice message (n = 160)
Number of subjects: 318
Study: 18377687

Group type: EXPERIMENTAL
Intervention: 25 g glucose
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 50 g glucose
Number of subjects: 33

Group type: COMPARATOR
Intervention: sweetness matched placebo drink
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: blood glucose concentration
Number of subjects: 33
Study: 16563170

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass surgery (CABG)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Standard on-pump CABG
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 561

Group type: COMPARATOR
Intervention: EQ-5D
Number of subjects: 561

Group type: COMPARATOR
Intervention: SF-6D
Number of subjects: 561
Study: 14585893

Group type: EXPERIMENTAL
Intervention: Spindle-aligned microinjection
Number of subjects: 246

Group type: COMPARATOR
Intervention: PB-aligned control group
Number of subjects: 246
Study: 11063177

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Droperidol (2.5 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 100
Study: 8891015

Group type: EXPERIMENTAL
Intervention: Micanol (dithranol micro-encapsulated in crystalline monoglycerides)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: UVB therapy
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of Micanol and UVB therapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dithranol treatment (previous studies)
Number of subjects: 8
Study: 2000823

Group type: COMPARATOR
Intervention: 0 mg beta-carotene/d
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 15 mg beta-carotene/d
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 45 mg beta-carotene/d
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 180 mg beta-carotene/d
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 300 mg beta-carotene/d
Number of subjects: 50
Study: 6655232

Group type: EXPERIMENTAL
Intervention: smoking under no stress
Number of subjects: 51

Group type: COMPARATOR
Intervention: sham smoking under no stress
Number of subjects: 51

Group type: COMPARATOR
Intervention: sham smoking under stress
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: smoking under stress
Number of subjects: 51
Study: 30985290

Group type: EXPERIMENTAL
Intervention: Dolutegravir with lamivudine or emtricitabine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Boosted darunavir with lamivudine or emtricitabine (Control)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Dolutegravir with boosted darunavir
Number of subjects: 58

Group type: COMPARATOR
Intervention: Raltegravir with boosted darunavir (Control)
Number of subjects: 58
Study: 29599299

Group type: EXPERIMENTAL
Intervention: Automated electronic alert system
Number of subjects: 2278

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2278
Study: 27215949

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) + Attention Control (AC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: COPD Education (COPD-ED) + Attention Control (AC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) + COPD Education (COPD-ED)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 70